ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TELA vs SRTS // NET PROFIT MARGIN

TELA Bio Inc. (NASDAQ) VS. Sensus Healthcare Inc. (NASDAQ) • 15-METRIC TALLY: TELA 2 — SRTS 6
▲ NET PROFIT MARGIN LEADER: SRTS
net-margins
-28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TELA VS. SRTS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TELA SRTS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 67.70% 43.20% +24.50 TELA /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -31.30% -3.70 SRTS /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — 0.73% — TIE /fcf-yield <GO>
Operating Margin -42.00% -37.50% -4.50 SRTS /operating-margins <GO>
Net Profit Margin ACTIVE -48.30% -28.10% -20.20 SRTS /net-margins <GO>
Revenue Growth (YoY) 15.80% -34.30% +50.10 TELA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 6.50 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 5/9 -1.00 SRTS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.8 39.3 -5.50 SRTS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $41.5M $45.6M -$4.1M SRTS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TELA REV SRTS REV TELA GROSS % SRTS GROSS % TELA FCF SRTS FCF
FY 2025 $80.3M $27.5M 67.7% 43.2% -$28.7M $332.0K
FY 2024 $69.3M $41.8M 67.1% 58.4% -$42.6M -$1.1M
FY 2023 $58.5M $24.4M — — -$40.9M -$2.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TELA // BETA —
SRTS // BETA —